Bristol-Myers Squibb Compnay

Novarock Biotherapeutics, Ltd.

Ming Lei

Haichun Huang

Alan J Korman

Mohan Srinivasan

Nils Lonberg

Aaron Paul Yamniuk

Karla Ann Henning

Bryan C Barnhart

Sandra V Hatcher

Liang Schweizer

Guodong Chen

Richard Y Huang

Maria N Jure-Kunkel

Martin J Corbett

John S Sack

Emanuela Sega

Angela Goodenough

Joseph E Myers, Jr

Pingping Zhang

Han Li

Yi Pei

Mark J Selby

Arvind Rajpal

Kent B Thudium

Changyu Wang

Han Chang

Mark F Maurer

Xi-Tao Wang

Michelle Minhua Han

Indrani Chakraborty

Brenda L Stevens

Jochem Gokemeijer

Huiming Li

Alexander T Kozhich

Thomas D Kempe

Michael Quigley

Susan Chien-Szu Wong

Xiang Shao

Hadia Lemar

Zhehong Cai

Marie-Michelle Navarro Garcia

Christina Maria Milburn

Patrick Guirnalda

Joseph E Myers

Praveen Aanur

Zheng Yang

Christine Huang

Yan Feng

Maria Rodriguez

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.

Anti-interleukin-23 P19 antibodies and methods of use thereof

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

Anti-CLauDiN 18 antibodies and methods of use thereof

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided herein are heavy chain constant regions (referred to as 'modified heavy chain constant regions'), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Antibodies comprising modified heavy constant regions

Antibodies against CD73

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.

Growing community of inventors

Princeton, NJ, United States of America

Ming Lei